Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 298

1.

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM.

Leukemia. 2010 Jul;24(7):1302-9. doi: 10.1038/leu.2010.113. Epub 2010 May 27.

PMID:
20508616
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.

Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A.

Leukemia. 2010 Jun;24(6):1146-51. doi: 10.1038/leu.2010.77. Epub 2010 Apr 22.

PMID:
20410924
[PubMed - indexed for MEDLINE]
3.

TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.

Martínez-Avilés L, Besses C, Álvarez-Larrán A, Torres E, Serrano S, Bellosillo B.

Ann Hematol. 2012 Apr;91(4):533-41. doi: 10.1007/s00277-011-1330-0. Epub 2011 Sep 9.

PMID:
21904853
[PubMed - indexed for MEDLINE]
4.

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.

Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A.

Leukemia. 2010 Oct;24(10):1713-8. doi: 10.1038/leu.2010.163. Epub 2010 Aug 19.

PMID:
20724988
[PubMed - indexed for MEDLINE]
5.

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.

Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA, McClure RF, Pardanani A.

Leukemia. 2012 Mar;26(3):475-80. doi: 10.1038/leu.2011.253. Epub 2011 Sep 13.

PMID:
21912393
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL.

Leukemia. 2009 May;23(5):905-11. doi: 10.1038/leu.2009.47. Epub 2009 Mar 5.

PMID:
19262601
[PubMed - indexed for MEDLINE]
7.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
[PubMed - indexed for MEDLINE]
8.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.

PMID:
19616600
[PubMed - indexed for MEDLINE]
9.

Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children.

Ismael O, Shimada A, Hama A, Sakaguchi H, Doisaki S, Muramatsu H, Yoshida N, Ito M, Takahashi Y, Akita N, Sunami S, Ohtsuka Y, Asada Y, Fujisaki H, Kojima S.

Pediatr Blood Cancer. 2012 Sep;59(3):530-5. doi: 10.1002/pbc.23409. Epub 2011 Nov 21.

PMID:
22106054
[PubMed - indexed for MEDLINE]
10.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
[PubMed - indexed for MEDLINE]
11.

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Tefferi A.

Leukemia. 2010 Jun;24(6):1128-38. doi: 10.1038/leu.2010.69. Epub 2010 Apr 29. Review.

PMID:
20428194
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
[PubMed - indexed for MEDLINE]
13.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

PMID:
17369568
[PubMed - indexed for MEDLINE]
Free Article
14.

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm.

Rumi E, Harutyunyan A, Elena C, Pietra D, Klampfl T, Bagienski K, Berg T, Casetti I, Pascutto C, Passamonti F, Kralovics R, Cazzola M.

Am J Hematol. 2011 Dec;86(12):974-9. doi: 10.1002/ajh.22166. Epub 2011 Sep 22.

PMID:
21953568
[PubMed - indexed for MEDLINE]
15.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.

PMID:
24366362
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
[PubMed - indexed for MEDLINE]
17.

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A.

Genes Chromosomes Cancer. 2012 Aug;51(8):743-55. doi: 10.1002/gcc.21960. Epub 2012 Apr 9.

PMID:
22489043
[PubMed - indexed for MEDLINE]
18.

EZH2 mutational status predicts poor survival in myelofibrosis.

Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM.

Blood. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14.

PMID:
21921040
[PubMed - indexed for MEDLINE]
Free Article
19.

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.

Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.

Ann Lab Med. 2012 Nov;32(6):385-91. doi: 10.3343/alm.2012.32.6.385. Epub 2012 Oct 17.

PMID:
23130336
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.

Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A; French Group of Familial Myeloproliferative Disorders.

Blood Cells Mol Dis. 2012 Oct 15-Dec 15;49(3-4):170-6. Epub 2012 Jul 19.

PMID:
22818858
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk